1. Home
  2. AGMB vs RGNX Comparison

AGMB vs RGNX Comparison

Compare AGMB & RGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo AgomAb Therapeutics NV American Depositary Shares

AGMB

AgomAb Therapeutics NV American Depositary Shares

N/A

Current Price

$5.54

Market Cap

576.2M

Sector

Health Care

ML Signal

N/A

Logo REGENXBIO Inc.

RGNX

REGENXBIO Inc.

N/A

Current Price

$7.17

Market Cap

487.2M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
AGMB
RGNX
Founded
2017
2008
Country
Belgium
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
576.2M
487.2M
IPO Year
2024
2015

Fundamental Metrics

Financial Performance
Metric
AGMB
RGNX
Price
$5.54
$7.17
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
7
11
Target Price
★ $37.67
$21.40
AVG Volume (30 Days)
297.3K
★ 1.1M
Earning Date
12-01-2026
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 18.08
EPS
★ N/A
N/A
Revenue
N/A
★ $10,393,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$24.01
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ 126.48
52 Week Low
$5.50
$5.46
52 Week High
$17.82
$16.19

Technical Indicators

Market Signals
Indicator
AGMB
RGNX
Relative Strength Index (RSI) 23.66 45.79
Support Level N/A $6.79
Resistance Level $9.55 $7.32
Average True Range (ATR) 0.69 0.59
MACD -0.04 -0.03
Stochastic Oscillator 5.17 19.32

Price Performance

Historical Comparison
AGMB
RGNX

About AGMB AgomAb Therapeutics NV American Depositary Shares

AgomAb Therapeutics NV is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology and inflammatory diseases, with an initial focus on chronic fibrotic indications with high unmet medical need. Its product candidates are designed to target established pathways and utilize validated modalities, with a focus on addressing limitations associated with prior treatment approaches. The company's pipeline includes small molecule and antibody product candidates aimed at targets associated with fibrotic diseases. Key candidates include Ontunisertib (AGMB-129) and AGMB-447.

About RGNX REGENXBIO Inc.

Regenxbio Inc is a clinical-stage biotechnology company focused on the development of gene therapy treatments. Its product candidates are designed to deliver genes to cells to address genetic defects or enable the production of therapeutic proteins. The company is developing a pipeline of investigational gene therapy treatments using its NAV Technology Platform based on adeno-associated virus (AAV) vectors. Its internal research and development programs are focused on therapies for retinal, neuromuscular, and neurodegenerative diseases.

Share on Social Networks: